PDS Biotechnology Highlights PDS0101 Data in Updated Presentation

The latest update is out from PDS Biotechnology ( (PDSB) ).

On February 23, 2026, PDS Biotechnology updated its corporate presentation, highlighting clinical data from its lead program PDS0101, which targets HPV16-positive head and neck cancers that currently lack approved targeted therapies. The company reported a median overall survival of 39.3 months, disease control and objective response rates of 77.4% and 35.8% respectively, and noted that these outcomes substantially exceed the typical 12–18 month median survival seen with the current standard Keytruda plus chemotherapy in recurrent or metastatic settings.

The deck underscores PDS’s extensive intellectual property estate, with more than 12 patent families providing exclusivity into the early 2040s across major global markets, and outlines a Phase 3 pivotal trial, VERSATILE-003, aligned with the U.S. FDA on an accelerated approval pathway using progression-free survival as the primary endpoint. By showcasing validation from prominent international cancer centers and detailing the Versamune platform’s mechanism for generating potent, tumor-specific T-cell responses, the update positions PDS Biotechnology as a potential first mover in targeted immunotherapy for HPV16-driven head and neck cancers, which could significantly influence its competitive standing and future commercial prospects if Phase 3 results are positive.

The most recent analyst rating on (PDSB) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on PDS Biotechnology stock, see the PDSB Stock Forecast page.

Spark’s Take on PDSB Stock

According to Spark, TipRanks’ AI Analyst, PDSB is a Neutral.

The score is held down primarily by weak financial performance (no revenue, persistent losses/cash burn, and a diminished equity base), which raises financing risk. Technicals are neutral with only mild signs of improvement, while positive trial/regulatory progress and recent patents/clinical updates provide some offset. Valuation support is limited because losses make the P/E not meaningful and no dividend yield is available.

To see Spark’s full report on PDSB stock, click here.

More about PDS Biotechnology

PDS Biotechnology is a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, with a particular emphasis on HPV16-driven head and neck cancers. Its lead asset, PDS0101 (Versamune HPV), is built on the company’s Versamune lipid nanoparticle platform, designed to train and direct T cells to precisely attack HPV16-positive tumors, addressing a growing unmet need in HPV16-positive head and neck cancer patients.

Average Trading Volume: 660,371

Technical Sentiment Signal: Strong Sell

Current Market Cap: $36.71M

For an in-depth examination of PDSB stock, go to TipRanks’ Overview page.